Artwork by Kathleen Sluka
A2CPS will collect questionnaires, blood samples and brain imaging from 2,800 participants before and for up to 12 months after having total knee replacement or thoracic surgery.
Many diseases can be diagnosed, tracked and predicted with biological markers, or biomarkers, but none are yet known for chronic pain. The major aim of A2CPS is to find biomarkers or bio-signatures of the transition to chronic pain.
The A2CPS consortium is organized into four main hubs, with over 100 investigators and staff around the country. Our researchers span a wide range of expertise, from basic scientists to clinicians to data management experts.
In addition to biological specimens, A2CPS also collects different types of data from our participants, including patient-reported outcomes (PROs) and quantitative sensory testing (QST), among others.
The term “omics” refers to the collection of information about the molecules found in our blood, which can tell us about the activity of genes, proteins, lipids and metabolites in our cells and tissues.
Previous studies have identified “signatures” of brain activity that reflect a painful experience, and others that predicted who was more likely to develop chronic pain. A2CPS will include brain-imaging data in our search for biosignatures of chronic pain.
Published Feb 2024
The A2CPS Consortium will gather in person March 26-27, hosted by Rush University in Chicago. A2CPS investigators are currently analyzing our baseline data, which will become available to researchers via the NIMH Data Archive (NDA) platform in summer 2024. Stay tuned for details.
A2CPS Investigator Joshua J. Jacobs, MD, FAAOS, was honored by the American Academy of Orthopaedic Surgeons (AAOS) with its 2024 William W. Tipton Jr., MD, Leadership Award, for his years of service to the profession and to his community. Congratulations, Dr. Jacobs!